Wellgistics expands healthcare ecosystem with tollo health agreement, targeting multi-billion dollar glp-1 and long covid market

Tampa, florida, feb. 26, 2025 (globe newswire) -- wellgistics health, inc. (nasdaq: wgrx, the "company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, wellgistics llc, has entered into an agreement with tollo health, llc (“tollo”) to market tollo's emerging proprietary suite of novel medical food products for glp-1 treatment-related side effects, including muscle loss and long covid to pharmacies. tollo is bringing to market novel, proprietary medical food products to address muscle loss and gut discomfort associated with glp-1 drug use, and persistent viral infection(s), gut discomfort, sarcopenia, immune dysregulation, cellular senescence, endothelial damage and general nutritional support for patients with long covid. tollo's first marketed product is galectovid™, a proprietary medical food for the dietary management of galectin-1 & 3 associated viral infections. further details on galectovid™ are available at www.galectovid.com .
WGRX Ratings Summary
WGRX Quant Ranking